UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.08
+3.78 (51.78%)
At close: Jun 12, 2025, 4:00 PM
11.99
+0.91 (8.21%)
After-hours: Jun 12, 2025, 7:59 PM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for UroGen Pharma stock ranges from a low of $3.00 to a high of $53.5. The average analyst price target of $22.92 forecasts a 106.86% increase in the stock price over the next year.
Price Target: $22.92 (+106.86%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +125.63% | Jun 12, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $36 → $10 | Buy | Maintains | $36 → $10 | -9.75% | Jun 3, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $40 → $15 | Strong Buy | Maintains | $40 → $15 | +35.38% | May 23, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $16 → $3 | Hold | Maintains | $16 → $3 | -72.92% | May 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 22, 2025 |
Financial Forecast
Revenue This Year
117.52M
from 90.40M
Increased by 30.00%
Revenue Next Year
238.28M
from 117.52M
Increased by 102.76%
EPS This Year
-3.01
from -2.96
EPS Next Year
-0.80
from -3.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 144.4M | 411.1M | 741.7M | ||
| Avg | 117.5M | 238.3M | 332.6M | ||
| Low | 97.2M | 125.0M | 143.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 59.7% | 249.8% | 211.3% | ||
| Avg | 30.0% | 102.8% | 39.6% | ||
| Low | 7.6% | 6.3% | -39.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.35 | 2.14 | 4.24 | ||
| Avg | -3.01 | -0.80 | 1.12 | ||
| Low | -3.64 | -1.95 | -0.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.